Ruxolitinib and vedolizumab salvage therapy in the setting of cytomegalovirus colitis for a patient with newly diagnosed very early onset inflammatory bowel disease.

Alison Laxer, Morris Edelman, Julie Gallagher, Benjamin Sahn

Abstract read

In one paragraph

Article in JPGN reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Ruxolitinib and vedolizumab salvage therapy in the setting of cytomegalovirus colitis for a patient with newly diagnosed very early onset inflammatory bowel disease.JPGN reports · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Alison LaxerDivision of Pediatric Gastroenterology Cohen Children's Medical Center New Hyde Park New York USA.ORCID https://orcid.org/0009-0001-9414-1706

Morris EdelmanDivision of Pediatric Pathology Cohen Children's Medical Center New Hyde Park New York USA.

Julie GallagherDivision of Pediatric Gastroenterology Cohen Children's Medical Center New Hyde Park New York USA.

Benjamin SahnDivision of Pediatric Gastroenterology Cohen Children's Medical Center New Hyde Park New York USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute severe ulcerative colitis increases the risk for cytomegalovirus (CMV) infection, particularly with the use of immunocompromising medications. We report a case of a 4-year-old with newly diagnosed very early onset inflammatory bowel disease presenting with acute severe colitis refractory to both corticosteroids and infliximab, whose course was complicated by CMV colitis. Clinical remission was achieved with combination salvage therapy of ruxolitinib and vedolizumab. Clearance of CMV was not impaired with this regimen. Initiating combination Janus Kinase inhibition and anti-integrin salvage therapy in the setting of CMV infection and acute severe colitis is not previously described.

Indexed as

acute severe colitiscombination therapyprimary nonresponse to antitumor necrosis factor‐α

Identifiers

PMID41695071

DOI10.1002/jpr3.70106

PMCPMC12894045

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.